Pfizer Reports Strong Q1 Operational Revenue Growth (Ex-COVID), Advances Strategic Pipeline, and Resolves Key Legal Matters

summarizeSummary

Pfizer reported Q1 2026 revenues of $14.5 billion, a 5% increase year-over-year, driven by 7% operational growth excluding COVID-19 products. The company continues its strategic restructuring, advances its pipeline with new approvals and filings, and resolves significant legal proceedings, while also noting new tariff risks.

check_boxKey Events

• Q1 Financial Performance

  Total revenues increased 5% to $14.5 billion in Q1 2026, compared to $13.7 billion in Q1 2025. Excluding contributions from Comirnaty and Paxlovid, total revenues increased 7% operationally. Diluted EPS decreased to $0.47 from $0.52 year-over-year.

• Strategic Portfolio Shift

  Strong operational growth was observed in key products including Padcev (+39%), Nurtec ODT/Vydura (+41%), Lorbrena (+32%), Abrysvo (+31%), Orgovyx (+43%), and Oncology biosimilars (+55%). This growth significantly offset declines in COVID-19 product revenues from Comirnaty (-59%) and Paxlovid (-63%).

• Cost Realignment and Synergies

  Multi-year cost realignment programs are progressing, with $4.3 billion incurred to date out of an expected $5.3 billion total, aiming for $5.7 billion in net cost savings through 2026. The Manufacturing Optimization Program has incurred $1.1 billion out of $1.4 billion, targeting $1.5 billion in net cost savings by 2027. Additionally, $600 million in annual cost synergies are expected from the Metsera acquisition by the end of 2026.

• Business Development Updates

  Pfizer completed the exit of its 11.7% investment in ViiV on March 31, 2026, receiving $1.875 billion in cash proceeds. The company also detailed its November 2025 acquisition of Metsera for $8.0 billion (including $2.3 billion in potential contingent value rights) and a February 2026 in-licensing arrangement with Sciwind Biosciences for up to $495 million for a GLP-1 receptor agonist in China.

auto_awesomeAnalysis

Pfizer's Q1 2026 report highlights a successful strategic pivot away from its COVID-19 product dependency, demonstrating robust operational growth in its core biopharmaceutical portfolio. While overall diluted EPS saw a slight decline year-over-year, the underlying strength in new and established non-COVID products, coupled with significant cost-saving initiatives and strategic acquisitions, positions the company for future growth. The resolution of several long-standing legal matters reduces uncertainty, though new tariff risks on patented pharmaceuticals bear close monitoring.